1. Repository of OAI
Ελληνικά   English  
Saved Searches

Discover

Search


Current filters:


Clear current filters  or Add more filters

View Option


Results 41-50 of 53 (Search time: 0.004 seconds).

  Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Journal article)

  Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up (Journal article)

  Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors (Journal article)

  Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study (Journal article)

  Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up (Journal article)

  Cancer of unknown primary site: missing primary or missing biology? (Journal article)

  Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study (Journal article)

  The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy (Journal article)

  Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study (Journal article)

  Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study (Journal article)